Finally, comparing tumor DNA results, 24 patients with BRAF, KRAS and NRAS mutations had shorter survival than 33 patients without these mutations (25 months vs. 61months, P=0.0334) (Figure 2A). This evidence concerns the gene BRAF and neoplasm.